Life Sciences

  • June 09, 2026

    Fed. Circ. 'Recalibrates' Analysis For Constitutional Standing

    The Federal Circuit eased the line between constitutional and statutory standing last month when reviving A.L.M. Holding Co.'s infringement suit against Zydex Industries Private Ltd., in a decision attorneys say makes standing more accessible and clarifies how patent licensors can maintain their rights.

  • June 09, 2026

    4th Circ. Revives Ex-Gilead Worker's Defamation Suit

    The Fourth Circuit revived Tuesday a lawsuit from a former biopharmaceutical company employee after finding that he'd sufficiently backed his claim for vicarious liability against Gilead Sciences Inc., but refused to draw a co-worker back into the case.

  • June 09, 2026

    Eli Lilly Wins Order Halting Alleged Trulicity Fraud

    A Florida federal judge signed off Tuesday on a preliminary injunction pausing a prescription cost share program purportedly for Church of God in Christ members that pharmaceutical giant Eli Lilly and Co. says is actually a fraud scheme to resell GLP-1 drug Trulicity on the secondary market.

  • June 09, 2026

    McKesson, Rite Aid Trust Clash Over Ch. 11 Claims Transfer

    McKesson locked horns Tuesday in New Jersey bankruptcy court with a trust created by Rite Aid's first Chapter 11 plan over whether the medication supplier must hand over antitrust claims against pharmaceutical companies.

  • June 09, 2026

    BioTech Co. Hit Investor Suit Over Cancer Test Trial Miss

    Biotechnology company Grail Inc. was hit with a proposed investor class action alleging that it misled investors about the likelihood its cancer screening blood test would demonstrate effectiveness in a clinical trial, which the public learned in February was unsuccessful.

  • June 09, 2026

    Biopharma Founder's Nonsolicit Clause Void Under Calif. Law

    A biopharmaceutical company's co-founder prevailed Monday in convincing North Carolina's business court that nonsolicitation restrictions in his contract were void after they were deemed unenforceable under California law.

  • June 09, 2026

    Ex-Zydus Unit Exec Alleges 'Second Class Citizen' Treatment

    A female executive at Zydus Pharmaceuticals' pet health unit said in New Jersey federal court that she was treated as a second-class citizen by her male counterparts, claiming she was constructively discharged due to the hostile and discriminatory conduct she faced because she is a woman.

  • June 09, 2026

    Novanta Buys Riverpoint In $1.45B Deal Steered By 3 Firms

    Medical technology provider Novanta Inc., advised by Ropes & Gray LLP and King & Spalding LLP, on Tuesday announced plans to acquire medical device maker Riverpoint Medical, led by Goodwin Procter LLP, from private equity shop Arlington Capital Partners in a deal worth up to $1.45 billion.

  • June 09, 2026

    4th Circ. Lets Hartford Unit Off The Hook For Drug Test Fight

    A Hartford unit doesn't owe coverage to a drug testing company accused of reporting false positive drug tests due to substandard quality control, the Fourth Circuit ruled Tuesday, saying the suit is related to an earlier claim that was covered by another insurer.

  • June 09, 2026

    The Law360 400: A Look At The Top 100 Firms

    The race to build the legal industry's largest law firm accelerated in 2025, with major firms leaning on mergers, lateral hiring and strategic expansion to climb the ranks of the Law360 400.

  • June 09, 2026

    Davis Polk, Slaughter & May Steer GSK's $10.6B Nuvalent Deal

    Pharma giant GSK PLC said Tuesday that it has agreed to acquire cancer therapy specialist Nuvalent Inc. for $10.6 billion as it seeks to accelerate its "rapid expansion" into the oncology market.

  • June 08, 2026

    Fed. Circ. Scrutinizes UT's 'Inflammatory' Comments In IP Trial

    The "inflammatory" language used by the University of Texas to secure a $42 million patent infringement verdict against Boston Scientific is "about as good an example as one can possibly think of," U.S. Circuit Judge Richard G. Taranto told the university's attorney on Monday.

  • June 08, 2026

    Eli Lilly Conspiracy Claim In Compound Drug Row Challenged

    A California federal court should toss part of Eli Lilly's third attempt at allegations that a telehealth company, provider group and a now-shuttered pharmacy conspired to falsely advertise compounded versions of its weight loss drugs, the companies argued in a recent motion.

  • June 08, 2026

    AIPLA, NAM Rally Behind Moderna's Fight Over Vax Patents

    The American Intellectual Property Law Association, National Association of Manufacturers and others urged the Federal Circuit to undo a lower court's ruling that Moderna, and not the government, must face a multibillion-dollar patent infringement suit over its COVID-19 vaccine.

  • June 08, 2026

    Fed. Circ. Panel Backs Invalidation Of OxyContin Patent

    The Federal Circuit on Monday upheld a Delaware federal court's decision that deemed invalid a Purdue Pharma patent covering an abuse-deterrent version of the opioid OxyContin, rebuffing the company's arguments that the lower court got its obviousness analysis wrong.

  • June 08, 2026

    Biogen To End Investors' Alzheimer's Drug Case For $18.9M

    Biogen Inc. has agreed to pay $18.9 million to exit a lawsuit accusing it of misleading investors about the commercial readiness of a new Alzheimer's treatment, according to a settlement filed in Massachusetts federal court.

  • June 08, 2026

    Goodwin, Fenwick Guide Incyte-Vega Deal Worth Up To $2B

    The biotechnology company Incyte said Monday it has entered into a definitive agreement to acquire Vega Therapeutics Inc. from Star Therapeutics for up to $2 billion, with Goodwin Procter LLP advising Incyte and Fenwick & West LLP representing Star Therapeutics. 

  • June 08, 2026

    Class Attys Want $11.6M In Fees From $35M Teva Inhaler Deal

    Berman Tabacco, Sperling Kenny Nachwalter LLC, Hilliard Shadowen LLP and five other firms have asked a Massachusetts federal judge for $11.55 million in attorney fees from a $35 million antitrust settlement resolving claims that Teva abused patent protections to delay generic competition for its QVAR asthma inhalers.

  • June 08, 2026

    Johnson & Johnson Paying $1B For Oncology Startup Firefly

    Johnson & Johnson said Monday it has agreed to acquire Firefly Bio Inc. for $1 billion in cash, adding a proprietary technology that targets hard-to-treat tumors. 

  • June 08, 2026

    Sleep Aid Buyers Say 'Non-Habit' Pills Can Cause Dependence

    A proposed class of sleep-aid buyers is suing the makers and sellers of Unisom, saying that despite being marketed with a prominent "non-habit forming" claim, its main ingredient has been known to lead to dependence with frequent use.

  • June 05, 2026

    Ex-Trader Accused Of Profiting From Cousin's Insider Info

    A retired New York Mercantile Exchange trader is charged with insider trading by securities regulators who allege he bought shares of Sanofi's biopharmaceutical unit Kadmon Holdings Inc. based on confidential information the trader received about Kadmon's flagship chronic graft-versus-host disease treatment drug in July 2021, and that the trader tipped off a friend about the information.

  • June 05, 2026

    JPML Denies Industrywide Spinal Device Injury MDL Bid

    The Judicial Panel on Multidistrict Litigation declined to consolidate dozens of product liability cases over spinal cord stimulator devices manufactured by Boston Scientific Corp., Abbott Laboratories, Nevro and Medtronic, finding Friday that while centralization of the actions against Boston Scientific was appropriate, an industrywide action was not.

  • June 05, 2026

    Trans Patients Urge Blocking DOJ 'Campaign Of Harassment'

    Transgender adolescents urged a California federal judge Friday to block a Stanford Medicine hospital from sharing gender-related care medical records in response to a Texas grand jury criminal subpoena, arguing that other courts have rebuffed similar government subpoena attempts and the judge should end the DOJ's "campaign of harassment."

  • June 05, 2026

    J&J Cleared Of Talc Liability In LA Bellwether Trial

    A Los Angeles jury cleared Johnson & Johnson of any liability in the deaths of three women from ovarian cancer, finding Friday following a six-week bellwether trial that the company's sales of talcum powder were not negligent. 

  • June 05, 2026

    IRhythm Inks $45M Deal With Investors In Heart Device Suit

    IRhythm Technologies Inc. investors asked a California federal judge to preliminarily greenlight a $45 million settlement resolving allegations the digital healthcare company inflated stock prices with misrepresentations about its heart-event monitoring device, noting the deal is a favorable result that warrants approval, given the possibility of no recovery. 

Expert Analysis

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here